Cassava Sciences (SAVA) Set to Announce Quarterly Earnings on Thursday

Cassava Sciences (NASDAQ:SAVA) is scheduled to release its earnings data before the market opens on Thursday, November 7th. Analysts expect Cassava Sciences to post earnings of ($1.37) per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

Cassava Sciences (NASDAQ:SAVA) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.57. During the same period last year, the firm earned ($0.63) earnings per share. On average, analysts expect Cassava Sciences to post $-6 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Cassava Sciences Price Performance

Shares of NASDAQ SAVA opened at $23.93 on Wednesday. The business has a 50-day moving average of $27.82 and a two-hundred day moving average of $22.92. The company has a market capitalization of $1.15 billion, a price-to-earnings ratio of -16.97 and a beta of -0.59. Cassava Sciences has a 1 year low of $8.79 and a 1 year high of $42.20.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on SAVA shares. Rodman & Renshaw reaffirmed a “buy” rating and issued a $107.00 price target on shares of Cassava Sciences in a report on Thursday, August 8th. HC Wainwright raised shares of Cassava Sciences from a “neutral” rating to a “buy” rating and set a $116.00 price target for the company in a research report on Tuesday, October 8th.

Cassava Sciences Company Profile

Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.